

Rituximab Intravenous Products Clinical Resource

Agents: Riabni™ (rituximab-arrx intravenous infusion – Amgen)
Rituxan® (rituximab intravenous infusion – Genentech)
Ruxience™ (rituximab-pvvr intravenous infusion – Pfizer)
Truxima® (rituximab-abbs intravenous infusion – Celltrion/Teva)
Rituxan Hycela (rituximab/hyaluronidase- Genentech)

Posting Date: 09/01/2022, revised 12/1/2022

Overview

Rituximab biosimilar products do not require prior authorization; however, the use of BRAND Rituxan requires an evaluation of medical necessity, prior to approval of use.

Rituximab/hyaluronidase is a combination product administered subcutaneously as the hyaluronidase increases the drug absorption.

Rituximab products are CD20-directed cytolytic antibodies. All approved rituximab intravenous products are indicated for treatment of the following conditions:

- **Chronic lymphocytic leukemia (CLL)**, in combination with fludarabine and cyclophosphamide (FC) for the treatment of patients with previously untreated and previously treated CD20-positive disease.
- **Granulomatosis with polyangiitis (Wegener's granulomatosis)** and **microscopic polyangiitis** in adults, in combination with glucocorticoids.
- **Non-Hodgkin lymphoma (NHL)**, for the following uses:
 - previously untreated follicular, CD20-positive disease, in combination with first-line chemotherapy, and in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as a single-agent maintenance therapy.
 - for relapsed or refractory, low-grade or follicular, CD20-positive, B-cell disease.
 - for non-progressing (including stable disease) low-grade, CD20-positive, B-cell disease as a single agent after first-line cyclophosphamide/vincristine/prednisone (CVP) chemotherapy.
 - for previously untreated diffuse large B-cell, CD20-positive disease, in combination with cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) or other anthracycline-based chemotherapy regimens.

In addition to the above indications, Rituxan intravenous and Truxima are also indicated for treatment of the following condition:

- **Rheumatoid arthritis**, in adult patients with moderately to severely active disease, in combination with methotrexate for patients who have had an inadequate response to one or more tumor necrosis factor inhibitors (TNFis).

In addition to the above indications, Rituxan intravenous is also indicated for treatment of the following conditions:

- **Granulomatosis with polyangiitis (Wegener's granulomatosis)** and **microscopic polyangiitis** in patients ≥ 2 years of age, in combination with glucocorticoids.
- **Pemphigus vulgaris**, for adults with moderate to severe disease.

Riabni, Ruxience, and Truxima are approved as biosimilar to Rituxan intravenous, indicating no clinically meaningful

differences in safety and effectiveness and the same mechanism of action, route of administration, dosage form, and strength as Rituxan intravenous. However, minor differences in clinically inactive components are allowed. At this time, the biosimilars have only demonstrated biosimilarity, not interchangeability. **Rituxan is not covered and requires review for medical necessity prior to its use.**

Similar to intravenous rituximab products, rituximab/hyaluronidase subcutaneous injection is indicated in follicular lymphoma, previously untreated diffuse large B cell lymphoma and chronic lymphocytic leukemia after patients have received at least one full dose of a rituximab product by intravenous infusion. It has not been evaluated for non-malignant conditions.⁴ Rituxan Hycela is NOT interchangeable with other rituximab products.

Guidelines

The use of rituximab is supported in clinical guidelines in numerous situations, both as first-line therapy and in patients who are refractory or have relapsed following treatment with other therapies.⁴⁻²¹

- **Immune Thrombocytopenia (ITP):** Guidelines from the American Society of Hematology (ASH) for ITP (2019) mention rituximab as an alternative for children and adults with ITP who do not respond to first-line treatment, and for adults who are corticosteroid-dependent.¹⁷
- **Multiple Sclerosis (MS):** In June 2019, a consensus paper was updated by the MS Coalition that discusses the use of disease-modifying therapies in MS.¹⁸ Rituximab is listed among various options, involving different mechanisms of action and modes of administration, which have shown benefits in patients with MS. The American Academy of Neurology has practice guidelines regarding disease-modifying therapies for adults with MS.¹⁹ The guidelines mention rituximab for use in MS.
- **Neuromyelitis Optica Spectrum Disorders:** A review article lists rituximab as an effective treatment for neuromyelitis optica.²⁰
- Oncology indications covered in National Comprehensive Cancer Network (NCCN) guidelines:⁶
 - **Acute Lymphoblastic Leukemia (ALL):** Guidelines (version 1.2021 – April 6, 2021) list rituximab in multiple regimens for Philadelphia chromosome (Ph)-negative disease.¹¹ In those with Ph-positive disease, rituximab should be considered in addition to chemotherapy for those with CD20-positive disease, especially in those < 60 years of age.
 - **B-Cell Lymphomas:** In the guidelines (version 4.2021 – May 5, 2021), rituximab is included in multiple treatment regimens across the spectrum of disease.⁸ Guidelines for pediatric aggressive mature B-cell lymphomas (version 2.2021 – June 7, 2021) include rituximab intravenous as a component of treatment regimens for induction therapy/initial treatment and as subsequent therapy for relapsed or refractory disease.⁹ For primary cutaneous B-cell lymphomas (version 2.2021 – March 4, 2021), rituximab is a treatment option for patients with primary cutaneous B-cell lymphoma.¹⁰
 - **CLL/Small Lymphocytic Lymphoma:** Rituximab features prominently in the guidelines (version 4.2021 – April 29, 2021) and is included in multiple treatment regimens across the spectrum of disease.⁷
 - **Graft-Versus-Host Disease (GVHD):** Guidelines (version 2.2021 – April 21, 2021) list rituximab among the agents used for steroid-refractory chronic GVHD.¹⁵
 - **Hairy Cell Leukemia:** Guidelines (version 2.2021 – March 11, 2021) recommend rituximab as a component in a preferred primary regimen, and in multiple regimens for relapsed/refractory disease (including in patients with progressive disease after relapsed/refractory therapy).¹²
 - **Hodgkin Disease:** Guidelines (version 4.2021 – April 20, 2021) recommend rituximab ± chemotherapy and/or radiation (depending on the clinical presentation) in the first-line setting for nodular lymphocyte-predominant disease.¹³ Rituximab is also used for relapsed/refractory disease and for maintenance.
 - **Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma:** Guidelines (version 1.2020 – September 1, 2020) include rituximab in regimens across the spectrum of disease (primary therapy, previously treated disease, and maintenance).¹⁴

- **Pemphigus Vulgaris:** British guidelines (2017) list rituximab in combination with corticosteroids as a first-line therapy.²³
- **Rheumatoid Arthritis:** Guidelines from the American College of Rheumatology (ACR) [2015] have tumor necrosis factor (TNF) inhibitors and non-TNF biologics (including rituximab), equally positioned following a trial of a conventional synthetic disease-modifying antirheumatic drug (DMARD).¹⁶
- **Systemic Lupus Erythematosus (SLE):** European League Against Rheumatism (EULAR) recommendations for the management of SLE (2019) mention rituximab as a therapeutic option for patients who are refractory to standard immunosuppressive therapies.²¹
- **Vasculitis:** EULAR and European Renal Association/European Dialysis and Transplant Association (ERA-EDTA) recommendations for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis mention rituximab in combination with low-dose corticosteroids as a potential treatment option for remission-maintenance therapy.⁴ Remission-maintenance therapy is recommended for at least 24 months following induction of sustained remission. British guidelines for use of rituximab in ANCA-associated vasculitis recommend rituximab for maintenance of remission to reduce the risk of relapse and its consequences.⁵

Clinical Guidance for Use

Use of rituximab intravenous products is recommended in those who meet the following criteria:

FDA-Approved Indications

Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.

- A) Induction Treatment** For 1 month for the following
- Patient has an ANCA-associated vasculitide; AND used in combination with glucocorticoids
- Note: Examples of ANCA-associated vasculitis include granulomatosis with polyangiitis (GPA) [Wegener's granulomatosis] or microscopic polyangiitis (MPA).
- B) Follow-Up Treatment of Patients Who Have Received Induction Treatment for ANCA-Associated Vasculitis.**
- Note: This includes a patient who received induction treatment using a rituximab product or other standard of care immunosuppressants.
- According to the prescriber, the patient achieved disease control with induction treatment; AND
 - If the patient previously received a course of therapy, at least 16 weeks will elapse between courses.

Dosing. Use one of the following (A or B):

- A) Induction Therapy:** 375 mg/m² per dose administered intravenously with doses separated by at least 7 days; OR
- B) Follow-Up Treatment of a Patient Who Has Received Induction Treatment for ANCA-Associated Vasculitis:** one of the following (i or ii):
- Up to two 500 mg doses administered as an intravenous infusion separated by at least 14 days, then up to 1,000 mg administered by intravenous infusion not more frequently than once every 6 months; OR
 - Up to two doses of 250 mg/m² administered as an intravenous infusion separated by at least 14 days, then 250 mg/m² administered by intravenous infusion not more frequently than once every 6 months.

B-Cell Lymphoma.

- A) Note:** Examples of B-Cell Lymphomas include Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Acquired Immune Deficiency (AIDS)-Related B-Cell Lymphoma, Burkitt Lymphoma, Castleman's Disease, Marginal Zone Lymphoma (e.g., extranodal or MALT [gastric or nongastric], nodal, or splenic marginal zone lymphoma), Primary Mediastinal Large B-Cell Lymphoma, Mantle Cell Lymphoma, Post-Transplant Lymphoproliferative Disorders, Gray Zone Lymphoma, Primary Cutaneous B-Cell Lymphoma, Pediatric Aggressive Mature B-cell Lymphomas.

Dosing. Use up to 375 mg/m² per dose administered intravenously with doses separated by at least 7 days.

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.

Dosing. Use up to 500 mg/m² administered as an intravenous infusion on 1 day of each cycle.

Pemphigus Vulgaris.

- A) Initial Treatment. Use for 1 month in combination with a corticosteroid unless contraindicated
- B) Relapse or for Maintenance of Pemphigus Vulgaris.
 - i. Subsequent infusions will be administered no sooner than 16 weeks following the previous infusion of a rituximab product
 - ii. A dermatologist should monitor/ consult on therapy

Dosing. Use one of the following (A or B):

- A) Initial Treatment or Treatment of a Relapse. Use one course of therapy, which consists of up to two 1,000-mg doses administered as an intravenous infusion separated by at least 2 weeks; OR
- B) Maintenance Therapy. Use up to 500 mg per dose administered intravenously.

Rheumatoid Arthritis.

- A) Initial Therapy. Consider use in patient who has tried ONE conventional synthetic disease-modifying antirheumatic drug (DMARD) for at least 3 months AND rituximab will not be used concurrently with another biologic or with a targeted synthetic DMARD
 - B) Patient has already Received One or More Courses of a Rituximab Product for Rheumatoid Arthritis. 16 weeks or greater will elapse between treatment courses; AND rituximab will not be used concurrently with another biologic or with a targeted synthetic DMARD
- Note: For example, there will be a minimum of 16 weeks since the first dose of the previous course and the first dose of the next course of a rituximab product.

Dosing. Use one course of therapy, which consists of up to two 1,000-mg intravenous doses separated by at least 2 weeks.

Other Uses with Supportive Evidence

Acute Lymphoblastic Leukemia. Use in CD20-positive disease

Dosing: Use up to 375 mg/m² administered intravenously with doses separated by at least 7 days.

Graft-Versus-Host Disease. Consider use if

- A) Patient has tried at least one conventional systemic treatment for graft versus host disease.
Note: Examples include systemic corticosteroids (methylprednisolone, prednisone), cyclosporine, tacrolimus, mycophenolate mofetil, Imbruvica (ibrutinib capsules and tablets), imatinib, antithymocyte globulin, Nipent (pentostatin infusion), or an infliximab product.
- B) **Dosing.** Use up to 375 mg/m² administered intravenously with doses separated by at least 7 days.

Hairy Cell Leukemia.

Dosing. Use up to 375 mg/m² administered intravenously with doses separated by at least 7 days.

Hodgkin Lymphoma. Consider use if the patient has nodular lymphocyte-predominant disease

Dosing. Use up to 375 mg/m² administered intravenously with doses separated by at least 7 days.

Immune Thrombocytopenia (ITP). Consider use if the patient has tried one other therapy such as intravenous immunoglobulin (IVIG), anti-D (RHO) immunoglobulin, corticosteroids, and splenectomy.

A) If Patient has Already Received a Course of a Rituximab Product for ITP.

- i. Consider use if after a minimum of 6 months separating the first dose of the previous course and the first dose of the subsequent course of a rituximab product AND
- ii. Patient responded to therapy as determined by the prescriber (e.g. platelet count increase from baseline following treatment with a rituximab product).; AND
- iii. The prescriber has determined that the patient has relapsed (e.g. patient experiences thrombocytopenia after achievement of a remission

B) Dosing. Use up to 375 mg/m² administered intravenously with doses separated by at least 7 days.

Multiple Sclerosis. Consider use if the patient had an inadequate response or was unable to tolerate at least ONE other disease-modifying agent for multiple sclerosis; AND

A) The medication will not be used concurrently with another disease-modifying agent used for multiple sclerosis; AND

B) At least 6 months will elapse between treatment courses (e.g. if the patient has already received a course of therapy there will be a minimum of 6 months separating the first dose of the previous course and the first dose of the subsequent course of therapy).

C) Dosing. Use up to 2,000 mg (total) administered as one or two intravenous infusions administered over 1 month.

Neuromyelitis Optica Spectrum Disorder.

Dosing. Use ONE of the following (A or B):

A) Up to 375 mg/m² administered intravenously with doses separated by at least 7 days; OR

B) Up to two 1,000-mg doses administered as an intravenous infusion separated by at least 2 weeks.

Primary Central Nervous System Lymphoma.

Dosing: Use up to 375 mg/m² administered intravenously with doses separated by at least 7 days.

Systemic Lupus Erythematosus (SLE) [Lupus] (including nephrotic syndrome in a patient with SLE).

A) Consider use in patient that has tried at least ONE standard immunomodulating or immunosuppressant agent

B) For a patient that has already received a course of a rituximab product for SLE. Use for 1 month (adequate duration to receive one course) if 6 months or greater will elapse between treatment courses (i.e., there will be a minimum of 6 months separating the first dose of the previous rituximab course and the first dose of the subsequent course of rituximab).

C) Dosing. Varies

Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma.

Dosing. Use up to 375 mg/m² administered intravenously with doses separated by at least 7 days.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Use of rituximab intravenous products is not recommended in the following situations:

1. Use is not recommended for circumstances where data do not support its use.

REFERENCES

1. Rituxan [prescribing information]. South San Francisco, CA: Genentech; August 2020.
2. Rituxan Hycela [prescribing information]. South San Francisco, CA: Genentech; Revised June 2021.
3. Ruxience [prescribing information]. New York, NY: Pfizer; May 2020.
4. Truxima [prescribing information]. North Wales, PA: Teva/Celltrion; May 2020.

5. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. *Ann Rheum Dis*. 2016;75(9):1583-1594.
6. Tieu J, Smith R, Basu N, et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. *Rheumatology (Oxford)*. 2020;59(4):e24-e32.
7. The NCCN Drugs and Biologics Compendium. © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 7, 2021. Search term: rituximab.
8. The NCCN Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Clinical Practice Guidelines in Oncology (Version 4.2021 – April 29, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 7, 2021.
9. The NCCN B-Cell Lymphoma Clinical Practice Guidelines in Oncology (Version 4.2021 – May 5, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 7, 2021.
10. The NCCN Pediatric Aggressive Mature B-cell Lymphomas Clinical Practice Guidelines in Oncology (Version 2.2021 – June 7, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 7, 2021.
11. The NCCN Primary Cutaneous Lymphomas Clinical Practice Guidelines in Oncology (Version 2.2021 – March 4, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 7, 2021.
12. The NCCN Acute Lymphoblastic Leukemia Clinical Practice Guidelines in Oncology (Version 1.2021 – April 6, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 7, 2021.
13. The NCCN Hairy Cell Leukemia Clinical Practice Guidelines in Oncology (Version 2.2021 – March 11, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 7, 2021.
14. The NCCN Hodgkin Lymphoma Clinical Practice Guidelines in Oncology (Version 4.2021 – April 20, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 7, 2021.
15. The NCCN Waldenstrom’s Macroglobulinemia/Lymphoplasmacytic Lymphoma Clinical Practice Guidelines in Oncology (Version 1.2021 – September 1, 2020). © 2020 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 7, 2021.
16. The NCCN Hematopoietic Cell Transplantation (HCT): pre-transplant recipient evaluation and management of graft versus host disease Clinical Practice Guidelines in Oncology (Version 2.2021 – April 21, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 7, 2021.
17. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol*. 2016;68(1):1-26.
18. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. *Blood Adv*. 2019;3(23):3829-3866.
19. A Consensus Paper by the Multiple Sclerosis Coalition. The use of disease-modifying therapies in multiple sclerosis. Updated June 2019. Available at: http://ms-coalition.org/wp-content/uploads/2019/06/MS_CDMTPaper_062019.pdf. Accessed on June 7, 2021.
20. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018;90:777-788.
21. Collongues N, de Seze J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. *Ther Adv Neurol Disord*. 2016;9(3):180-188.
22. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. 2019;78(6):736-745.
23. Riabni [prescribing information]. Thousand Oaks, CA: Amgen; December 2020.
24. Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists' guidelines for the management of pemphigus vulgaris 2017. *Br J Dermatol*. 2017;177(5):1170-1201.

Created: 07/22

Effective Date: 9/1/2022, revised 12/1/2022

Gateway Approval: 8/10/2022

P & T Approval: N/A